Related references
Note: Only part of the references are listed.Effects and Side Effects of Using Sorafenib and Sunitinib in the Treatment of Metastatic Renal Cell Carcinoma
Caroline Randrup Hansen et al.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES (2017)
LCZ696 ( Valsartan/Sacubitril) - A Possible New Treatment for Hypertension and Heart Failure
Mathilde Borring Andersen et al.
BASIC & CLINICAL PHARMACOLOGY & TOXICOLOGY (2016)
A Phase II Trial of the Multitargeted Tyrosine Kinase Inhibitor Lenvatinib (E7080) in Advanced Medullary Thyroid Cancer
Martin Schlumberger et al.
CLINICAL CANCER RESEARCH (2016)
Phase 2 clinical trial of sunitinib as adjunctive treatment in patients with advanced differentiated thyroid cancer
Athanasios Bikas et al.
EUROPEAN JOURNAL OF ENDOCRINOLOGY (2016)
Prognostic significance of adverse events in patients with hepatocellular carcinoma treated with sorafenib
Alessandro Granito et al.
THERAPEUTIC ADVANCES IN GASTROENTEROLOGY (2016)
Lenvatinib: Role in thyroid cancer and other solid tumors
Maria E. Cabanillas et al.
CANCER TREATMENT REVIEWS (2016)
Latest Results for Anti-Angiogenic Drugs in Cancer Treatment
Sofie Frandsen et al.
CURRENT PHARMACEUTICAL DESIGN (2016)
Effects and Role of Multikinase Inhibitors in Thyroid Cancer
Rasmus Laursen et al.
CURRENT PHARMACEUTICAL DESIGN (2016)
Spotlight on lenvatinib in the treatment of thyroid cancer: patient selection and perspectives
Ricardo Costa et al.
DRUG DESIGN DEVELOPMENT AND THERAPY (2016)
Influence of Tyrosine Kinase Inhibitors on Hypertension and Nephrotoxicity in Metastatic Renal Cell Cancer Patients
Aleksandra Semeniuk-Wojtas et al.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES (2016)
Third-Generation Beta-Adrenoceptor Antagonists in the Treatment of Hypertension and Heart Failure
Filip Y. Fisker et al.
BASIC & CLINICAL PHARMACOLOGY & TOXICOLOGY (2015)
A Phase 2 Trial of Lenvatinib (E7080) in Advanced, Progressive, Radioiodine-Refractory, Differentiated Thyroid Cancer: A Clinical Outcomes and Biomarker Assessment
Maria E. Cabanillas et al.
CANCER (2015)
Subgroup analysis of Japanese patients in a phase 3 study of lenvatinib in radioiodine-refractory differentiated thyroid cancer
Naomi Kiyota et al.
CANCER SCIENCE (2015)
Safety and tolerability of sorafenib in patients with radioiodine-refractory thyroid cancer
Francis Worden et al.
ENDOCRINE-RELATED CANCER (2015)
Differentiated thyroid cancer
V. Tiedje et al.
INTERNIST (2015)
Comparative risk of renal, cardiovascular, and mortality outcomes in controlled, uncontrolled resistant, and nonresistant hypertension
John J. Sim et al.
KIDNEY INTERNATIONAL (2015)
Lenvatinib, everolimus, and the combination in patients with metastatic renal cell carcinoma: a randomised, phase 2, open-label, multicentre trial
Robert J. Motzer et al.
LANCET ONCOLOGY (2015)
Prognostic Indicators in Well-Differentiated Thyroid Carcinoma When Controlling for Stage and Treatment
Kaelyn A. Krook et al.
LARYNGOSCOPE (2015)
Lenvatinib versus Placebo in Radioiodine-Refractory Thyroid Cancer
Martin Schlumberger et al.
NEW ENGLAND JOURNAL OF MEDICINE (2015)
Endothelin Antagonism and Hypertension: An Evolving Target
Luke J. Laffin et al.
SEMINARS IN NEPHROLOGY (2015)
Treatment of sunitinib-induced hypertension in solid tumor by nitric oxide donors
L. Leon-Mateos et al.
REDOX BIOLOGY (2015)
Inhibition of the VEGF signalling pathway and glomerular disorders
Mario Ollero et al.
NEPHROLOGY DIALYSIS TRANSPLANTATION (2015)
Vascular Endothelial Growth Factor Inhibitor-Induced Hypertension: From Pathophysiology to Prevention and Treatment Based on Long-Acting Nitric Oxide Donors
Peter Kruzliak et al.
AMERICAN JOURNAL OF HYPERTENSION (2014)
Hypertension Due to Antiangiogenic Cancer Therapy With Vascular Endothelial Growth Factor Inhibitors: Understanding and Managing a New Syndrome
Heather Yvonne Small et al.
CANADIAN JOURNAL OF CARDIOLOGY (2014)
Poorly differentiated thyroid cancer
Kepal N. Patel et al.
CURRENT OPINION IN OTOLARYNGOLOGY & HEAD AND NECK SURGERY (2014)
A phase II trial of sunitinib in women with metastatic or recurrent endometrial carcinoma: A study of the Princess Margaret, Chicago and California Consortia
Vincent Castonguay et al.
GYNECOLOGIC ONCOLOGY (2014)
Anti-Vascular Endothelial Growth Factor Therapy in Breast Cancer
Tina Bogelund Kristensen et al.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES (2014)
Impact of Achieved Blood Pressures on Mortality Risk and End-Stage Renal Disease Among a Large, Diverse Hypertension Population
John J. Sim et al.
JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY (2014)
Sorafenib in radioactive iodine-refractory, locally advanced or metastatic differentiated thyroid cancer: a randomised, double-blind, phase 3 trial
Marcia S. Brose et al.
LANCET (2014)
Blood pressure and incidence of twelve cardiovascular diseases: lifetime risks, healthy life-years lost, and age-specific associations in 1.25 million people
Eleni Rapsomaniki et al.
LANCET (2014)
Management of Sorafenib-Related Adverse Events: A Clinician’s Perspective
Marcia S. Brose et al.
SEMINARS IN ONCOLOGY (2014)
Management of Common Adverse Events in Patients Treated With Sorafenib: Nurse and Pharmacist Perspective
Christine M. Walko et al.
SEMINARS IN ONCOLOGY (2014)
2013 ESH/ESC Guidelines for the management of arterial hypertension
Giuseppe Mancia et al.
BLOOD PRESSURE (2013)
Cancer incidence and mortality patterns in Europe: Estimates for 40 countries in 2012
J. Ferlay et al.
EUROPEAN JOURNAL OF CANCER (2013)
Biomarkers for Anti-Angiogenic Therapy in Cancer
Markus Wehland et al.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES (2013)
Current Understanding and Management of Medullary Thyroid Cancer
Madhuchhanda Roy et al.
ONCOLOGIST (2013)
Genomic Approach to Identify Factors That Drive the Formation of Three-Dimensional Structures by EA.hy926 Endothelial Cells
Xiao Ma et al.
PLOS ONE (2013)
Phase II Trial of Sorafenib in Patients with Advanced Anaplastic Carcinoma of the Thyroid
Panayiotis Savvides et al.
THYROID (2013)
Clinical, Safety, and Economic Evidence in Radioactive Iodine-Refractory Differentiated Thyroid Cancer: A Systematic Literature Review
Roger T. Anderson et al.
THYROID (2013)
Cardiovascular complications associated with novel angiogenesis inhibitors: Emerging evidence and evolving perspectives
Steven M. Bair et al.
TRENDS IN CARDIOVASCULAR MEDICINE (2013)
The Effects of Newer Beta-Adrenoceptor Antagonists on Vascular Function in Cardiovascular Disease
Markus Wehland et al.
CURRENT VASCULAR PHARMACOLOGY (2012)
Sunitinib-Induced Systemic Vasoconstriction in Swine Is Endothelin Mediated and Does Not Involve Nitric Oxide or Oxidative Stress
Mariette H. W. Kappers et al.
HYPERTENSION (2012)
Management of Antiangiogenic Therapy-Induced Hypertension
Nilka de Jesus-Gonzalez et al.
HYPERTENSION (2012)
VEGF Inhibition, Hypertension, and Renal Toxicity
Suzanne R. Hayman et al.
CURRENT ONCOLOGY REPORTS (2012)
Rationale and design of decision: a double-blind, randomized, placebo-controlled phase III trial evaluating the efficacy and safety of sorafenib in patients with locally advanced or metastatic radioactive iodine (RAI)-refractory, differentiated thyroid cancer
Marcia S. Brose et al.
BMC CANCER (2011)
Phase I Dose-Escalation Study and Biomarker Analysis of E7080 in Patients with Advanced Solid Tumors
Kazuhiko Yamada et al.
CLINICAL CANCER RESEARCH (2011)
Sunitinib Malate for the Treatment of Pancreatic Neuroendocrine Tumors.
Eric Raymond et al.
NEW ENGLAND JOURNAL OF MEDICINE (2011)
Hypertension Induced by the Tyrosine Kinase Inhibitor Sunitinib Is Associated With Increased Circulating Endothelin-1 Levels
Mariette H. W. Kappers et al.
HYPERTENSION (2010)
Standard and Emerging Therapies for Metastatic Differentiated Thyroid Cancer
Christine J. O'Neill et al.
ONCOLOGIST (2010)
Management of hypertension in angiogenesis inhibitor-treated patients
H. Izzedine et al.
ANNALS OF ONCOLOGY (2009)
Vascular endothelial growth factor induces extracellular matrix proteins and osteopontin in the umbilical artery
Manfred Infanger et al.
ANNALS OF VASCULAR SURGERY (2008)
Hypertension and rarefaction during treatment with telatinib, a small molecule angiogenesis inhibitor
Neeltje Steeghs et al.
CLINICAL CANCER RESEARCH (2008)
Phase II trial of sorafenib in advanced thyroid cancer
Vandana Gupta-Abramson et al.
JOURNAL OF CLINICAL ONCOLOGY (2008)
Uncovering Pandora's vase: the growing problem of new toxicities from novel anticancer agents. The case of sorafenib and sunitinib
C. Porta et al.
CLINICAL AND EXPERIMENTAL MEDICINE (2007)
The clinical toxicity profile of vascular endothelial growth factor (VEGF) and vascular endothelial growth factor receptor (VEGFR) targeting angiogenesis inhibitors; A review
Ferry A. L. M. Eskens et al.
EUROPEAN JOURNAL OF CANCER (2006)
Vascular endothelial growth factor signaling pathways: Therapeutic perspective
Marcin Kowanetz et al.
CLINICAL CANCER RESEARCH (2006)
Induction of three-dimensional assembly and increase in apoptosis of human endothelial cells by simulated microgravity: Impact of vascular endothelial growth factor
M. Infanger et al.
APOPTOSIS (2006)
Intraluminal application of vascular endothelial growth factor enhances healing of microvascular anastomosis in a rat model
M Infanger et al.
JOURNAL OF VASCULAR RESEARCH (2005)
Vascular endothelial growth factor: Basic science and clinical progress
N Ferrara
ENDOCRINE REVIEWS (2004)
Share Paper
